On June 17, 2026, Boston Scientific Corp BSX shares fell 4.2% to $44.95, continuing a downward trend that has seen the stock decline by 52.9% year-to-date and 55.8% over the past year. The stock has fluctuated between a 52-week high of $109.50 and a low of $44.79.
- GF Valueâ„¢ verdict: Current price of $44.95 is 57.3% below the GF Valueâ„¢ of $105.30.
- GF Scoreâ„¢ of 75/100 indicates the stock is rated above average based on key financial metrics.
- Notable signal: Insiders have bought $0.6M worth of shares in the last 3 months, with no selling activity observed.
Is BSX Overvalued or Undervalued?
With a GF Valueâ„¢ of $105.30, Boston Scientific Corp is currently trading at a significant discount to its intrinsic value, as indicated by its current price of $44.95. This presents a margin of safety of approximately 57.3%, suggesting that the stock is significantly undervalued at this time. The GF Valuation label classifies BSX as "Significantly Undervalued," highlighting a potential buying opportunity for investors. GF Valueâ„¢ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation might suggest a favorable entry point, investors should remain cautious of the underlying reasons for the stock's current price decline, including market conditions and company performance factors. The substantial dip in share price year-to-date points to potential risks that could affect future recovery and performance.
How Does BSX's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 18.8x | 67.9x |
| Forward P/E | 13.3x | N/A |
Boston Scientific's current P/E ratio of 18.8x is significantly below its 5-year median P/E of 67.9x, indicating that the stock is trading well below its historical valuation levels. The forward P/E of 13.3x suggests further potential for earnings growth. This P/E analysis aligns with the GF Valueâ„¢ verdict, reinforcing the assessment that BSX is undervalued based on its historical trading multiples.
What Does BSX's GF Scoreâ„¢ Tell Us?
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 75/100 |
| Financial Strength | 6/10 |
| Profitability | 9/10 |
| Growth | 10/10 |
| Valuation | 2/10 |
| Momentum | 1/10 |
The GF Scoreâ„¢ of 75/100 suggests that Boston Scientific Corp is positioned above average in terms of financial health and growth potential. Notably, the company achieves high scores in Profitability (9/10) and Growth (10/10), indicating robust operational performance and strong potential for future expansion. However, the Valuation (2/10) and Momentum (1/10) scores highlight significant concerns regarding its current market valuation and recent price performance, which could pose challenges moving forward.
What Are Insiders Doing with BSX Stock?
In recent months, insiders at Boston Scientific Corp have shown confidence in the company by purchasing $0.6 million worth of shares, with no reported selling activity. This insider buying could be interpreted as a positive signal, suggesting that those closest to the company believe in its future potential and are taking action to invest in it at current prices.
Such insider activity can be a strong indicator of management's confidence in the company’s prospects, which may provide additional reassurance to potential investors amid the stock's recent price declines.
What This Means for Investors
Based on the analysis of GF Valueâ„¢, Boston Scientific Corp is currently undervalued. The significant margin of safety suggests that the stock could present a compelling opportunity for long-term investors looking for potential growth, although caution is advised due to the current market conditions.
For the complete analysis, visit the Boston Scientific Corp BSX stock page. You can also explore the GF Valueâ„¢ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is BSX's GF Scoreâ„¢?
BSX's GF Scoreâ„¢ is 75/100, indicating that the stock is rated above average based on key financial metrics that suggest potential for higher long-term returns.
Is BSX overvalued or undervalued?
BSX is currently undervalued, trading at a price of $44.95, which is 57.3% below its GF Valueâ„¢ of $105.30.
What is BSX's P/E ratio?
BSX's P/E ratio (TTM) is 18.8x, which is significantly below its 5-year median P/E of 67.9x, indicating the stock is trading at a much lower valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
